Evidence Hub

Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis

Rayan Mohamed‐Ahmed, A. Rantell, D. Robinson

European Journal of Obstetrics & Gynecology and Reproductive Biology, 2026

5,317 participants · 1 citation

Abstract

INTRODUCTION: Overactive bladder (OAB) is defined as 'urinary urgency with or without urinary urgency incontinence (UUI), usually associated with urinary frequency and/or nocturia, in the absence of urinary tract infection'. OAB is known to be a common disorder with a significant impact on quality of life. First line treatments include weight loss in those with a BMI > 30, bladder retraining and fluid advice. Pharmacotherapy treatment includes antimuscarinics and mirabegron, a beta 3 agonist. The National Institute of Clinical Excellence (NICE), has recently incorporated the use of a newer beta 3 agonist, vibegron, into its recommendations for the management of overactive bladder (OAB). There are no head-to-head studies which directly compare the efficacy of vibegron with mirabegron, an older beta 3 agonist. AIM: This network meta-analysis aims to compare the safety and efficacy of vibegron when compared to mirabegron and tolterodine, more longstanding treatments for OAB. METHOD: A systematic review was conducted to identify phase III randomised controlled trials, for patients with idiopathic OAB, which compared mirabegron and/or vibegron and/or tolterodine. The primary outcome was the change from baseline in episodes of urinary urgency (UU). The secondary outcomes assessed were:The study was registered on PROSPERO (CRD 420250636077) and analysis was performed using MetaInsight. RESULTS: Of the 2,647 identified articles, five studies were deemed suitable to include in the…

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 5,317 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free